



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Edward P. Cohen

Examiner: G. Bansal

Serial No.: 09/522,716

Art Unit: 1642

Filed: March 10, 2000

Docket: 10464A

For: CANCER IMMUNOTHERAPY
WITH SEMI-ALLOGENEIC CELLS

Dated: February 25, 2002

9
60
47702

RECEIVED

MAR 08 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following disclosure, which is also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. U.S. Patent Application No. 6,228,357 BI, dated May 8, 2001, to Maudsley. The reference teaches a cancer therapy using an oncogene product and a foreign MHC molecule.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on February 25, 2002.

Dated: February 25, 2002


Anna Baerga

03/07/2002 MAHRED1 00000085 193886 09522716

02 FC:126 180.00 CH

H:\WORK\030\10464a\MISC\10464a.ID3

2. International Application No. WO 98/14205, published April 9, 1998. The reference teaches a cancer therapy using an oncogene product and a foreign MHC molecule.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(d), the \$180.00 fee is enclosed.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
FSD/XZ:ab